DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for reflex sympathetic dystrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleReflex sympathetic dystrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for reflex sympathetic dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
farnesyl diphosphate synthase (FDPS) — FDPS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-hydroxy-2-imidazo[1,2-a]pyridin-3-ylethane-1,1-diyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2VF6 · 2.1 Å · ligand (1-HYDROXY-2-IMIDAZO[1,2-A]PYRIDIN-3-YLETHANE-1,1-DIYL)BIS(PHOSPHONIC ACID) (M0N). Experimental structure, not a prediction.
What the evidence adds up to
In a 1985 study of 71 patients with reflex sympathetic dystrophy of the lower extremities, 27 were managed conservatively and 43 received sympathetic nerve blocks. At the three-year evaluation, 11 of the 27 conservative patients (41%) showed signs of improvement, compared with 28 of the 43 block patients (65%). The authors suggested that early treatment with repeated sympathetic nerve blocks appeared to improve long-term outcome. A 1989 review noted that some patients improve without treatment, while others develop intractable symptoms even after the injury has healed, and that a delay in diagnosis or treatment can result in severe physical and psychological problems.
A 1993 report on 35 patients with reflex sympathetic dystrophy found that peripheral nerve compression was present in 30 patients (86%). Half of those 30 had a single nerve compression and half had multiple compressions. The authors recommended checking for this treatable problem early in the course of the condition. A 1996 review reiterated that early recognition and appropriate intervention are the cornerstone of successful treatment.
A 2012 review of the literature stated that the pathogenesis of reflex sympathetic dystrophy is not clearly known and that no management protocol has been established. It reported that treatment of longstanding disease is empirical and of limited efficacy, and that outcomes are often unpredictable and of variable efficacy. The review noted that the disease may lead to dreadful sequelae requiring amputation and that a few patients may develop suicidal tendencies. Treatment options listed included pharmacological methods, sympathetic nervous system interruption, calcitonin, and bisphosphonate. The review concluded that more study is required to find the mechanism that triggers pain and other clinical manifestations so that a standardised management protocol can be developed.
What is still missing is a clear understanding of the underlying pathophysiology, a standardised treatment protocol, and prospective trials that stratify patients by the presence of nerve compression or by duration of disease. The evidence base remains limited to small case series and narrative reviews, with no large randomised controlled trials establishing the efficacy of any single intervention.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pain · 1985 · 88 citations
Sympathetic blocks for reflex sympathetic dystrophy
AbstractSeventy-one patients with reflex sympathetic dystrophy of the lower extremities were studied during a 3-year period. Of the 27 patients managed by conservative means, 11 (41%) showed signs of improvement 3 years after the onset of syndrome. Of the 43 patients treated by sympathetic nerve blocks, 28 (65%) experienced progress at the 3-year evaluation. Data suggest that early treatment with repeated sympathetic nerve blocks appears to improve the long-term outcome.
Clinical Orthopaedics and Related Research · 1989 · 31 citations
Reflex Sympathetic Dystrophy of the Lower Extremity
AbstractReflex sympathetic dystrophy (RSD) is a complex syndrome of pain, trophic changes, and vasomotor instability secondary to an abnormal hyperactive state of the sympathetic nervous system following injury to an extremity. Numerous theories have been proposed to explain the pathophysiology. None is universally accepted. The diagnosis of RSD is complicated because some patients improve without treatment, whereas others develop intractable symptoms even after the injury has healed. A delay in diagnosis and/or treatment for this syndrome can result in severe physical and psychological problems. Early recognition and prompt treatment, i.e., sympathetic blockade and physical therapy, provide the greatest opportunity for a successful outcome.
Journal of Hand Surgery (European Volume) · 1993 · 28 citations
The Association of Peripheral Nerve Compression and Reflex Sympathetic Dystrophy
Abstract35 patients who presented with reflex sympathetic dystrophy (RSD) are reported. Peripheral nerve compression was present in 86% of the patients (30). 50% of the patients (15) had a single nerve compression, and 50% had multiple nerve compressions. The high incidence of these entrapments should alert the clinician to check for this treatable problem early in the course of RSD.
Disability and Rehabilitation · 1996 · 13 citations
Reflex sympathetic dystrophy syndrome: diagnosis and treatment
AbstractThe reflex sympathetic dystrophy syndrome is a very common, poorly recognized syndrome which is associated with marked disability in some cases. The historical aspects, current ideas about the pathogenesis and pathophysiology, clinical features and staging are discussed. Early recognition and appropriate intervention are the cornerstone of successful treatment and are also discussed.
Bangladesh Journal of Medical Science · 2012 · 0 citations · open access
Review of Treatment of Reflex Sympathetic Dystrophy
AbstractA review study was done by searching literature through PubMed. Reflex sympathetic dystrophy is a life altering disease pathogenesis of which are not yet clearly known likewise its management protocol has not been established. Treatment of longstanding Reflex sympathetic dystrophy is empirical and of limited efficacy. This disease may lead to dreadful squeal which may need amputation for their management and few of these patients may even develop suicidal tendency. Patient with Reflex sympathetic dystrophy usually present late. It was found that the clinical presentation of RSD are too much variable, although different modalities of treatment are used either alone or in combination, the outcomes are often unpredictable and of variable efficacy. Understanding of the treatment modalities and proper selection of treatment option are essential for best outcome. Preventive measure does play a role in management of these patients. Option of treatment includes pharmacological method, sympathetic nervous system interruption, use of calcitonin and bisphosphonate. More study is required to find out the mechanism that triggers the pain and other clinical manifestation so that a standardized protocol for its management can be developed DOI: http://dx.doi.org/10.3329/bjms.v11i3.11714 Bangladesh Journal of Medical Science Vol. 11 No. 03 July12
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
